TrialDiabetes, obesity & metabolism2021

Long-term (52-week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT-2 study.

Eiichi Araki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.